Researchers are working on a type of vaccine technology using nanoparticles that is less expensive and does not need to be stored at very low temperatures compared to the mRNA technology used by BioNTech-Pfizer and Moderna to develop vaccines against Covid-19.
Moderna Inc. and Vertex Pharmaceuticals Incorporated announced a new strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for the treatment of cystic fibrosis (CF).
Novavax Inc. said South Korea’s SK bioscience would manufacture a component of the U.S. drug developer’s experimental coronavirus vaccine in a bid to boost the clinical-stage biotechnology company’s supply.
With rising numbers of COVID-19 infections and as the fight against the novel coronavirus continues, Novavax received $1.6 billion in federal funding to support the clinical development of the company’s vaccine candidate NVX‑CoV2373.
Maryland-based Novavax enrolled and dosed the company’s first patients in a Phase I/II study for a COVID-19 vaccine candidate.
Tianjin, China’s CanSino Biologics entered into a co-development agreement with Vancouver, British Columbia’s Precision NanoSystems for an mRNA lipid nanoparticle vaccine against COVID-19.
Maryland-based Novavax snagged $384 in additional grant funding to advance the company’s vaccine candidate against COVID-19.
Jaydev Thakkar was named chief operating officer and Milan Shah was appointed chief technology officer of Biofourmis
Researchers developed a type of nanoparticle that can “eat debris” related to the plaques that cause heart attacks.